AtriCure's preliminary Q4 revenue rises 13%, slightly beats estimates

AtriCure

12/01/2026 15:31

Overview

Surgical treatments innovator's preliminary Q4 revenue rose 13%, slightly beating analyst expectations

Company's Q4 revenue driven by growth in Pain Management, Open Ablation and AtriClip devices

Company projects 2026 revenue growth of 12% to 14% over 2025

Outlook

AtriCure projects 2026 revenue of $600 mln to $610 mln

Company expects 2026 adjusted EBITDA of $80 mln to $82 mln

AtriCure anticipates full year net income and positive cash flow in 2026

Result Drivers

PRODUCT LINE GROWTH - Q4 revenue driven by strong growth in Pain Management, Open Ablation, and AtriClip devices

INTERNATIONAL REVENUE - International revenue increased by 15%

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$140.50 mln
$139.27 mln (9 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for AtriCure Inc is $50.00, about 20.6% above its January 9 closing price of $41.46

Press Release: ID:nBw9lpglda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)